This trial will test if ZX008 is an effective and safe adjunctive therapy for people with uncontrolled seizures due to CDKL5 deficiency disorder.
1 Primary · 3 Secondary · Reporting Duration: 14 Weeks
Experimental Treatment
Non-Treatment Group
100 Total Participants · 3 Treatment Groups
Primary Treatment: ZX008 (Fenfluramine Hydrochloride) · Has Placebo Group · Phase 3
Age 1 - 35 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: